- Report Scope:
- Key Opinion Leaders (KOLs) offer views on the past, present, and future trends in supportive care in oncology
- Epidemiological insight on cancer and cancer supportive care
- Overview of market landscape and available therapies
- Unmet needs and opportunities identified in each indication
Traditionally an overlooked field, supportive oncology is growing across the 7MM (US, France, Germany, Italy, Spain, UK and Japan) and this growth will continue in the next 5-10 years.
Evidence suggests that supportive care increases the likelihood of finishing treatment, without the need for dose reductions or pauses in treatment. It can also reduce costs for healthcare institutions and improve quality of life for patients—all of which will become increasingly important as patients continue to live longer, and cancer becomes more like a chronic disease.
Despite oncology trends towards targeted therapies and new modalities of treatment such as immunotherapies, KOLs agree that chemotherapy will remain the backbone of cancer treatment for the next 5-10 years. Therefore, as the incidence of cancer rises, so will cases of chemotherapy-related conditions, in addition to a rise in general oncology-related conditions.